|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Houghton SC and Hankinson SE: Cancer
progress and priorities: Breast cancer. Cancer Epidemiol Biomarkers
Prev. 30:822–844. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fahad Ullah M: Breast cancer: Current
perspectives on the disease status. Adv Exp Med Biol. 1152:51–64.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Taskindoust M, Thomas SM, Sammons SL,
Fayanju OM, DiLalla G, Hwang ES and Plichta JK: Survival outcomes
among patients with metastatic breast cancer: Review of 47,000
patients. Ann Surg Oncol. 28:7441–7449. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang X, Shao X, Huang J, Lei L, Huang Y,
Zheng Y, Cao W and Chen Z: Exploring the concepts and practices of
advanced breast cancer treatment: A narrative review. Ann Transl
Med. 9:7212021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Shao W, Halachmi S and Brown M: ERAP140, a
conserved tissue-specific nuclear receptor coactivator. Mol Cell
Biol. 22:3358–3372. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Durand M, Kolpak A, Farrell T, Elliott NA,
Shao W, Brown M and Volkert MR: The OXR domain defines a conserved
family of eukaryotic oxidation resistance proteins. BMC Cell Biol.
8:132007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Finelli MJ, Sanchez-Pulido L, Liu KX,
Davies KE and Oliver PL: The evolutionarily conserved
Tre2/Bub2/Cdc16 (TBC), lysin motif (LysM), domain catalytic (TLDc)
domain is neuroprotective against oxidative stress. J Biol Chem.
291:2751–2763. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Eaton AF, Brown D and Merkulova M: The
evolutionary conserved TLDc domain defines a new class of
(H+)V-ATPase interacting proteins. Sci Rep. 11:226542021.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Castroflorio E, den Hoed J, Svistunova D,
Finelli MJ, Cebrian-Serrano A, Corrochano S, Bassett AR, Davies B
and Oliver PL: The Ncoa7 locus regulates V-ATPase formation and
function, neurodevelopment and behaviour. Cell Mol Life Sci.
78:3503–3524. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Khan H, Winstone H, Jimenez-Guardeño JM,
Graham C, Doores KJ, Goujon C, Matthews DA, Davidson AD, Rihn SJ,
Palmarini M, et al: TMPRSS2 promotes SARS-CoV-2 evasion from
NCOA7-mediated restriction. PLoS Pathog. 17:e10098202021.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Doyle T, Moncorgé O, Bonaventure B,
Pollpeter D, Lussignol M, Tauziet M, Apolonia L, Catanese MT,
Goujon C and Malim MH: The interferon-inducible isoform of NCOA7
inhibits endosome-mediated viral entry. Nat Microbiol. 3:1369–1376.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Guo J, Ke S, Chen Q, Zhou J, Guo J and Qiu
T: NCOA7 regulates growth and metastasis of clear cell renal cell
carcinoma via MAPK/ERK signaling pathway. Int J Mol Sci.
24:115842023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Arai H, Ozaki T, Niizuma H, Nakamura Y,
Ohira M, Takano K, Matsumoto M and Nakagawara A: ERAP140/Nbla10993
is a novel favorable prognostic indicator for neuroblastoma induced
in response to retinoic acid. Oncol Rep. 19:1381–1388.
2008.PubMed/NCBI
|
|
15
|
Lu J, Annunziata F, Sirvinskas D, Omrani
O, Li H, Rasa SMM, Krepelova A, Adam L and Neri F: Establishment
and evaluation of module-based immune-associated gene signature to
predict overall survival in patients of colon adenocarcinoma. J
Biomed Sci. 29:812022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xie X, Jiang Y, Yuan Y, Wang P, Li X, Chen
F, Sun C, Zhao H, Zeng X, Jiang L, et al: MALDI imaging reveals
NCOA7 as a potential biomarker in oral squamous cell carcinoma
arising from oral submucous fibrosis. Oncotarget. 7:59987–60004.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Higginbotham KSP, Breyer JP, Bradley KM,
Schuyler PA, Plummer WD Jr, Freudenthal ME, Trentham-Dietz A,
Newcomb PA, Sanders ME, Page DL, et al: A multistage association
study identifies a breast cancer genetic locus at NCOA7. Cancer
Res. 71:3881–3888. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Wu T, Peng Z, Tian X, Dai Q, Chen M,
Zhu J, Xia S, Sun A, Yang W and Lin Q: ETS1 is a prognostic
biomarker of triple-negative breast cancer and promotes the
triple-negative breast cancer progression through the YAP
signaling. Am J Cancer Res. 12:5074–5084. 2022.PubMed/NCBI
|
|
19
|
Umemura S, Kurosumi M, Moriya T, Oyama T,
Arihiro K, Yamashita H, Umekita Y, Komoike Y, Shimizu C, Fukushima
H, et al: Immunohistochemical evaluation for hormone receptors in
breast cancer: A practically useful evaluation system and handling
protocol. Breast Cancer. 13:2322006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sun A, Tian X, Yang W and Lin Q:
Overexpression of SCYL1 is associated with progression of breast
cancer. Curr Oncol. 29:6922–6932. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu J, Peng Z, Tian X, Wu T, Sun A, Yang W
and Lin Q: Activation of E3 ubiquitin ligase WWP2 by non-receptor
tyrosine kinase ACK1. IUBMB Life. 75:595–608. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Peng K, Sun A, Zhu J, Gao J, Li Y, Shao G,
Yang W and Lin Q: Restoration of the ATG5-dependent autophagy
sensitizes DU145 prostate cancer cells to chemotherapeutic drugs.
Oncol Lett. 22:6382021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Saez RA, McGuire WL and Clark GM:
Prognostic factors in breast cancer. Semin Surg Oncol. 5:102–110.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Esteva FJ, Sahin AA, Cristofanilli M, Arun
B and Hortobagyi GN: Molecular prognostic factors for breast cancer
metastasis and survival. Semin Radiat Oncol. 12:319–328. 2002.
View Article : Google Scholar : PubMed/NCBI
|
